ANNOUNCING BEDROCAN AS SILVER PARTNER OF CANNABIS EUROPA LONDON 2019

ANNOUNCING BEDROCAN AS SILVER PARTNER OF CANNABIS EUROPA LONDON 2019

Cannabis Europa is pleased to introduce Bedrocan as a Silver Partner for the London conference on the June 24th-25th at the Southbank Centre. Since 2003, Bedrocan has been producing standardised cannabis of pharmaceutical quality for the Dutch government. It’s the oldest legal cannabis company in the world, providing several chemically different cannabis varieties for prescription and for raw materials for the pharmaceutical industry (API). Bedrocan CEO Tjalling Erkelens speaking at the inaugural Cannabis Europa in London. “When it comes to medicinal cannabis,” says founder and CEO Tjalling Erkelens, “The world is changing. And it’s changing fast. Now that the EU,...

A HISTORIC MOMENT FOR EUROPEAN MEDICAL CANNABIS

A HISTORIC MOMENT FOR EUROPEAN MEDICAL CANNABIS

Cannabis Europa brought international stakeholders, fresh perspectives and stimulating discussion to Paris to drive forward Europe’s burgeoning medical cannabis space. On February 8th, Cannabis Europa was proud to host our first French conference, at Paris’ Maison de la Chimie. This world-renowned scientific institution, just steps from the Assemblée Nationale, is known for its commitment to partnering top-level scientists with decision-makers to foster science-based solutions for society. After a sparkling Welcome Reception the evening before, the full-day conference featured a series of deep dives into the complex regulatory landscape, groundbreaking scientific research, and the technical and business expertise that gives the...

A BIG THANKS TO CANACCORD GENUITY FOR HOSTING WELCOME DRINKS FOR CANNABIS EUROPA PARIS

A BIG THANKS TO CANACCORD GENUITY FOR HOSTING WELCOME DRINKS FOR CANNABIS EUROPA PARIS

Cannabis Europa wants to thank Canaccord Genuity for hosting the welcome drinks reception for our Paris conference. Alex Brooks, Senior Analyst at Canacord Genuity, will be speaking on the the Cannabis Capital panel. Through its principal subsidiaries, Canaccord Genuity is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry -: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage...

PANEL LINEUP – PHARMA FUTURES

PANEL LINEUP – PHARMA FUTURES

PHARMA FUTURES PETIT AMPITHEATER 12:35-13:35 Do France’s strong hemp and pharmaceutical industries give it a competitive edge in medical cannabis production? Is greater collaboration between international medical cannabis producers and the pharmaceutical giants in Europe needed to further legitimise the development of the industry? How will biosynthesis impact the production of cannabinoid medicines? What are the benefits of full spectrum products versus extracts/isolated compound products? To what extent are patents applicable to phytocannabinoids? CHAIR: Sofia Sanz With more than 10 years expertise in the healthcare Industry, Sofia Sanz worked as Business Development & Sales Manager at Alcaliber, a world leading...

PANEL LINEUP – IN CONVERSATION

PANEL LINEUP – IN CONVERSATION

IN CONVERSATION PETIT AMPITHEATER 15:45-16:45 CHAIR: Laura Jane Gautier Laura-Jane Gautier is a journalist and panel moderator. She started her carrier on several French TV Shows and later worked in different news channels, with a focus on economics. For two years she’s been doing daily interviews of CEOs, startups, lawyers and media personnel. Today Laura-Jane is a self-employed journalist and moderates panels on topics such as digital transformation, tech, public policies, politics, social business or artificial intelligence. Bernard Kouchner Bernard Kouchner is a French doctor and politician, co-founder of Médecins Sans Frontières and Médecins du Monde, and former Minister from...

PANEL LINEUP – POLITICAL SUBSTANCE

PANEL LINEUP – POLITICAL SUBSTANCE

POLITICAL SUBSTANCE (FR) PETIT AMPITHEATER 10:15-11:15 French and Canadian politicians join medical professionals and regulators to break down the issues, goals and hindrances surrounding medical cannabis regulation in France. CHAIR: Pierre-Yves Geoffard Pierre-Yves Geoffard is a French economist specialising in health economics. He has been director of the Paris School of Economics since 2013, director of studies at EHESS since 2008 and director of research at CNRS since 2003. He also writes an economic column in the newspaper Libération. Olivir Véran Olivir Véran is a neurologist at the Grenoble Hospital and MP for La République En Marche. After the publication...

PANEL LINEUP – LOCAL GLOBAL

PANEL LINEUP – LOCAL GLOBAL

LOCAL GLOBAL (FR) EUROPA STAGE – 15:45-16:45 What impact would a European Parliament resolution to regulate medical cannabis have on member states? What is the role of each level of government in promoting and ensuring responsible drug policy reform? How can we facilitate the sharing of knowledge and best practice between policy makers in Europe? How will the outcome of the WHO’s review into the international scheduling of cannabis affect government stances on the drug in Europe and worldwide? Could France’s regulation of medical cannabis (alongside Germany and the UK) ‘tip the scales’ of medical cannabis access in Europe? With...

PANEL LINEUP – WORLD STAGE

PANEL LINEUP – WORLD STAGE

WORLD STAGE EUROPA STAGE – 14:45-15:45 What will be the value of Canada’s first-mover advantage as Europe’s industry grows? Are some European countries already becoming early leaders in sections of the industry (R&D, cultivation, processing)? Does the fragmented nature of the European market help or hinder the birth of a European medical cannabis powerhouse? To what extent is Africa’s medical cannabis industry expected to disrupt the European and global industry? CHAIR: Alfredo Pascual Alfredo Pascual is a Germany-based International Analyst for Marijuana Business Daily, specialising in international cannabis markets and regulations. With an academic background in business and public policy,...

PANEL LINEUP – CANNABIS CAPITAL

PANEL LINEUP – CANNABIS CAPITAL

CANNABIS CAPITAL EUROPA STAGE – 12:35-13:35 How do investment opportunities in the European cannabis industry compare to that of North America? What drives the explosion of interest in cannabis investment, and what positive – and negative – effects could this have? When and how will institutional investors move into the industry at scale? Which adjacent industries will most benefit from the medical cannabis boom? Are Paris and Zurich likely to become the European hubs for medical cannabis investment after Brexit? Stephen Murphy Stephen is Group Managing Director and co-founder of European Cannabis Holdings. As a cannabis specialist focused on developing...

PANEL LINEUP – TRUST IN TRIALS

PANEL LINEUP – TRUST IN TRIALS

TRUST IN TRIALS EUROPA STAGE – 11:15-12:15 What role do clinical trials play in EU medicines regulation? How can we encourage cooperation between universities and private bodies to facilitate clinical trials? Is it ethical for physicians to prescribe cannabis-based medicines without clinical trials to back their efficiency and safety? Are clinical trials an absolute necessity for regulatory authorisation and doctors’ willingness to prescribe in Europe? How are medical cannabis patents enforceable? CHAIR: Hélène Moore Hélène Moore is a dynamic pharmaceutical and life sciences executive with substantial experience in the North American and European markets. Hélène is currently leading corporate development...

PANEL LINEUP – POLITICAL PATIENTS

PANEL LINEUP – POLITICAL PATIENTS

PETIT AMPITHEATER 14:45-15:45 How can we narrow the window between the political decision to allow medical cannabis and actual access for patients? Should patients have a right to cultivate cannabis for personal use? How to secure access to medical cannabis for patients travelling outside the Schengen area but remaining within European territory? Are government de-stigmitisation campaigns needed to educate the public about the use of medical cannabis? Can France become a model for medical cannabis insurance? CHAIR: Aurélien Bernard Aurélien Bernard is a French-born cannabis entrepreneur. He is the founder of the first French cannabis media company Newsweed, and is...

PANEL LINEUP – THE ‘IT’ DRUG

PANEL LINEUP – THE ‘IT’ DRUG

PETIT AMPITHEATER 11:15-12:15 French and Canadian politicians join medical professionals and regulators to break down the issues, goals and hindrances surrounding medical cannabis regulation in France. CHAIR: Joanna Weaver Pélissier Joanna is co-founder and CEO of Be Cann, a French enterprise involved in EU investments, certified raw cannabinoid materials, and developing cosmetic and nutraceutical products that are quality-controlled, effective and eco-responsible. Striving to help create a healthy, professional and sustainable legal cannabis industry in France and Europe, Joanna works closely with emerging brands, educators and scientists across the globe, facilitating propitious connections and forward-thinking collaborations. Laure Bougen Laure Bouguen is...

PANEL LINEUP – BUSY CEOS CEOs

PANEL LINEUP – BUSY CEOS CEOs

EUROPA STAGE – 10:15 – 11:15 The first English Panel of February’s Cannabis Europa will include CEOs from medical cannabis companies from around the world discuss the expected impact of the latest developments in the industry. CHAIR: George McBride George McBride is a former commercial barrister turned cannabis reform advocate and industry consultant based in London, UK. George was part of the founding team who setup Volteface, the UK’s leading think tank driving the debate around cannabis reform. He’s also a co-founder and CEO of Hanway Associates, London’s global cannabis consultancy; a team of creatives, consultants and academics. They consult,...

ANNOUNCING MGC PHARMACEUTICALS AS THE R&D PARTNER FOR CANNABIS EUROPA PARIS

ANNOUNCING MGC PHARMACEUTICALS AS THE R&D PARTNER FOR CANNABIS EUROPA PARIS

Cannabis Europa is proud to announce MGC Pharmaceuticals as the R&D Partner for our Paris conference February 8th at Maison de la Chimie. MGC Pharmaceuticals is an EU based biopharma company, creating a seamless pipeline of high quality, pharmaceutical grade products, taking advantage of the medical value of phytocannabinoids. MGC Pharma’s goal is to facilitate the transformation of phytocannabinoids into true medicinal product pipelines and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives. Research-focused Cannabis Europa Paris will focus on the relationship between the pharmaceutical industry and the medical cannabis industry. Cannabis-based...

ANNOUNCING PHYTOPLANT RESEARCH AS A BRONZE PARTNER FOR CANNABIS EUROPA PARIS

ANNOUNCING PHYTOPLANT RESEARCH AS A BRONZE PARTNER FOR CANNABIS EUROPA PARIS

Cannabis Europa is proud to announce Phytoplant Research as a Bronze Partner for our Paris conference on February 8th at Maison de la Chimie. Phytoplant Research S.L. is a privately owned Spanish company founded in 2008 which specialises in the field of phytotherapy research, the science-based medical use of plants. Phytoplant helps research and develop products in pharmaceutical, nutritional and skin care industries.  Phytoplant’s ‘passion for science and cannabinoid research’, is emblematic of the Cannabis Europa ideal to move the European industry forward with the highest standards of science.  Phytocannabinoids Phytocannabinoids are cannabinoids – active compounds – that occur naturally...

ANNOUNCING ZENABIS AS OUR LUNCH PARTNER FOR CANNABIS EUROPA PARIS

ANNOUNCING ZENABIS AS OUR LUNCH PARTNER FOR CANNABIS EUROPA PARIS

Cannabis Europa is proud to announce Zenabis as our Lunch Partner for Cannabis Europa Paris on February 8th. Zenabis is a significant licensed cannabis cultivator of medical and recreational cannabis in Canada, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state of the art greenhouses in Langley provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production space. If all facility space is dedicated to production,...

WHAT IMPACT WOULD FRANCE LEGALISING MEDICAL CANNABIS HAVE ON OTHER EUROPEAN COUNTRIES?

WHAT IMPACT WOULD FRANCE LEGALISING MEDICAL CANNABIS HAVE ON OTHER EUROPEAN COUNTRIES?

Europe is fast-changing on the issue of medical cannabis, with 21 countries in the European Union now allowing cannabis products to be used therapeutically in some form. Each country is going about the change in different ways however, creating a messy map of complicated policy on medical cannabis. The UK and France have been, perhaps, the most conservative in this regard, but the UK took a huge step last year in rescheduling cannabis. Now, eyes turn to France to see whether they will follow. The French Medicines Agency (ANSM) recently recommended that medical cannabis be authorised, sparking a nationwide discussion....

ANNOUNCING BE CANN AS A BRONZE PARTNER FOR CANNABIS EUROPA PARIS

ANNOUNCING BE CANN AS A BRONZE PARTNER FOR CANNABIS EUROPA PARIS

Cannabis Europa is proud to announce Be Cann as a bronze partner for our Paris conference February 8th at Maison de la Chimie. Be Cann is a diversified French company that specialises in the research and development of applications using natural cannabis extracts. Cannabis Europa aims to forge partnerships with organisations who can both drive the French market forward, and help facilitate cooperation between emerging business actors in Europe and the global cannabis market. Opening the French Market European countries are already becoming leaders in certain segments of the industry. Last year, France saw a surge in demand for CBD...

WHAT LESSONS CAN THE MEDICAL CANNABIS INDUSTRY LEARN FROM THE PHARMACEUTICAL INDUSTRY?

WHAT LESSONS CAN THE MEDICAL CANNABIS INDUSTRY LEARN FROM THE PHARMACEUTICAL INDUSTRY?

As the medical cannabis industry blossoms in Europe, there is an urgent need to consider the cross-over between the nascent cannabis business and the established pharmaceutical industry. Growing public support for medical cannabis is pushing progressive legislation in an increasing number of countries. As Cannabis Europa Paris approaches on February 8th, we examine what knowledge the cannabis industry can take from the development of the pharmaceutical industry. BREAKING THE BARRIERS Developing medical cannabis products has unique difficulties incomparable to modern medical products. Firstly, there is the taboo around cannabis to consider and the legal restrictions within most countries, despite recent...

ANNOUNCING EMMAC LIFE SCIENCES AS A SILVER PARTNER FOR CANNABIS EUROPA PARIS

ANNOUNCING EMMAC LIFE SCIENCES AS A SILVER PARTNER FOR CANNABIS EUROPA PARIS

Cannabis Europa is proud to announce EMMAC Life Sciences as a silver partner for our Paris conference on February 8th at Maison de la Chimie. EMMAC Life Sciences is a European independent medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. Cannabis Europa aims to drive forward the conversation on the role of science in cannabis and spearhead key debates in the pharmaceutical space. Thought Leader in Europe Led by seasoned industry executives and consultants, EMMAC is an industry leader in the UK and European medical cannabis space. With supply and...